Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain
Laboratory studyOther animalsWith 2-arachidonoyl glycerol and JZL184 (a MAGL inhibitor), tested alone; PEA was a measured lipid
This study tested palmitoylethanolamide together with 2-arachidonoyl glycerol and JZL184 (a MAGL inhibitor), tested alone; PEA was a measured lipid. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Female BALB/c mice given intraperitoneal paclitaxel (numbers not stated in the abstract)
- Dose used in the study
- 2-AG or JZL184 by subcutaneous injection into the right hind paw; doses not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Anandamide, 2-AG, palmitoylethanolamide and oleoylethanolamide in brain, spinal cord and paw skin by LC-MS/MS; MAGL protein in paw skin; mechanical allodynia; effect of CB1 and CB2 antagonists.
What the authors reported
Paclitaxel lowered 2-AG in paw skin only; anandamide, PEA and OEA were not significantly changed, and MAGL expression was unchanged. Local 2-AG or JZL184 reduced allodynia in the injected paw but not the other paw, and the 2-AG effect was blocked by both CB1 and CB2 antagonists.
Limits of this study
A mouse model of chemotherapy neuropathy; it cannot show effect in people. PEA was measured, not given, and did not change. Funding and conflicts not stated in the abstract.
Source
PubMed 32603895 · doi:10.1016/j.biopha.2020.110456
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.